Ricardo Macarron has been named president-elect of the Society for Biomolecular Screening, SBS said last week.
Macarron is the director of assay development at GlaxoSmithKline in Collegeville, Penn. Maccaron will become president of the society at its April 2007 conference and exhibition in Montreal. He received a PhD in biochemistry and a BS in biological sciences from Complutense University in Madrid.
David Onions has been promoted to chief medical officer of Invitrogen, a new position, the company said last week.
Onions was previously chief scientific officer for BioReliance, a company Invitrogen acquired in 2004. As CMO, Onions will be responsible for guiding Invitrogen's scientific efforts as it moves into areas more closely associated with medical research and closer to patients. He is also a personal chair in veterinary molecular virology at the University of Glasgow. Onions holds a PhD from the University of Cambridge and a BVSc from Bristol University.
John Murphy will resign as executive vice president and chief operating officer of PerkinElmer on Oct. 22, the company said in an SEC filing last week.
Murphy departs "for personal reasons relating to his decision not to relocate from California to Massachusetts," according to PerkinElmer.
Accelrys said last week that Mathew Hahn has been appointed chief science and technology officer.
Hahn began working at Acclerys in 1989 when the company was called Molecular Simulations. In 1999, he co-founded SciTegic, which Accelrys subsequently acquired in Sept. 2004. Hahn rejoined Accelrys as general manager of the SciTegic subsidiary. Hahn will remain general manager of SciTegic. He holds a PhD from the University of Santa Cruz.